Original article

Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain

Arantxazu Isla a, Iñaki F. Trocóniz b, Andrés Canut c, Alicia Labora c, José Emilio Martín-Herrero d, José Luis Pedraz a, Alicia R. Gascón a,∗

a Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain
b Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain
c Microbiology Unit. Santiago Apóstol Hospital, Vitoria, Spain
d Medical Department. GlaxoSmithKline, Tres Cantos, Madrid, Spain

A R T I C L E   I N F O

Article history:
Received 5 October 2009
Accepted 5 May 2010
Available online 22 February 2011

Keywords:
Acute otitis media
Children
Amoxicillin
Ceftriaxone
Streptococcus pneumoniae
Haemophilus influenzae

A B S T R A C T

Introduction: Acute otitis media is the most common respiratory tract infection in infancy and early childhood that is managed with antimicrobial agents. Ninety-three per cent of the cases diagnosed in Spain are treated with antibiotics, and Streptococcus pneumoniae and untypeable Haemophilus influenzae are the most frequently isolated pathogens. The aim of this work was to evaluate the usefulness of amoxicillin, amoxicillin/clavulanate and ceftriaxone for the empirical treatment of acute otitis media, looking at the pharmacokinetic variability and the antimicrobial susceptibility of paediatric strains of the two main pathogens responsible for AOM in Spain, Streptococcus pneumoniae and Haemophilus influenzae.

Methods: Free-drug plasma concentrations were simulated and the probability of target attainment at each minimum inhibitory concentration and the cumulative fraction of response (CFR) were determined. Microbiological susceptibility information was extracted from SAUCE 3 surveillance.

Results: CFR with amoxicillin varied from 83% to 96% against S. pneumoniae and from 78% to 86% against H. influenzae. CFR was always >85% with amoxicillin/clavulanate. With the 3-day ceftriaxone regimen, the probability of achieving free concentrations above MIC at 72 hours significantly increased compared to the single dose, with which CFR ranged from 70% to 84%.

Conclusions: High-dose amoxicillin (at least 80 mg/kg/day) should be the first-line therapy in uncomplicated infections, whereas amoxicillin/clavulanate (40 mg/kg/day) should be the choice when additional coverage for H. influenzae is desired. Administration of 3 daily doses of ceftriaxone increases bacteriological eradication probability when compared with one-day regimen, although additional clinical evaluations are necessary to establish the best target attainment with ceftriaxone.

© 2009 Elsevier España, S.L. All rights reserved.

Palabras clave:
Otitis media aguda
Niños
Amoxicilina
Ceftriaxona
Streptococcus pneumoniae
Haemophilus influenzae

R E S U M E N

Introducción: La otitis media aguda (OMA) es la infección del tracto respiratorio más común en la infancia que es tratada con agentes antimicrobianos. El noventa y tres por ciento de los casos diagnosticados en España se tratan con antibióticos, siendo Streptococcus pneumoniae y Haemophilus influenzae no tipable los patógenos aislados más frecuentes. El objetivo de este trabajo ha sido evaluar la utilidad de amoxicilina, amoxicilina/clavulanato y ceftriaxona en el tratamiento empírico de OMA teniendo en cuenta la variabilidad farmacocinética y la sensibilidad antimicrobiana de las cepas pediátricas de los dos patógenos principales responsables de OMA en España, Streptococcus pneumoniae y Haemophilus influenzae.
Introduction

Acute otitis media (AOM) is the most common respiratory tract infection in infancy and early childhood that is managed with antimicrobial agents. Ninety-three per cent of the cases diagnosed as AOM in Spain are treated with antibiotics, and Streptococcus pneumoniae and Haemophilus influenzae are the most frequently isolated pathogens.

It is well known that antibiotics shorten the course of AOM, but many cases remit spontaneously with no complications. Thus clinicians should avoid prescribing antibiotics routinely. Initial observation seems to be suitable for many children, if follow-up can be assured, whereas antibiotic treatment may be necessary in the very young (spontaneous resolution is lower in children younger than 2 years) or in severe or prolonged cases. When antibiotic therapy is indicated, selection of the most appropriate antibiotic should be based on the patient’s risk factors, physical examination, symptoms, local resistance patterns and treatment guidelines. By using pharmacokinetic (PK) and pharmacodynamic (PD) principles, an evaluation of the usefulness of treatments with antibiotics can be made in order to predict the likelihood of a successful clinical outcome.

In patients treated with β-lactams, bacteriolar eradicación can be predicted if free drug concentrations at the site of infection are above the minimum inhibitory concentrations (FT>MIC) of the pathogen for a time interval that exceeds 40%-50% of the dosing interval.

In a recent study, we evaluated the antimicrobial treatments in children with AOM in Spain taking into account the PK/PD approach. Only ceftriaxone and high-dose amoxicillin/clavulanate provided adequate efficacy indexes against S. pneumoniae and H. influenzae. Macrolides and azithromycin were not included in the study as they should not be empirically used in Spain due to the resistance of S. pneumoniae.

In that study, neither PK nor PD variability were considered. But, in fact, all organisms display a range of susceptibilities to any given antibiotic. Besides, a distribution of serum antibiotic concentration is observed in any population receiving the same antibiotic. Thus, the main objective of this work was to evaluate the usefulness of amoxicillin, amoxicillin/clavulanate and ceftriaxone for the treatment of AOM in Spain, assessing the probability of achieving the requisite PD exposure against S. pneumoniae and H. influenzae and taking into account the PK and PD variability in a simulated paediatric population.

Methods

Acquisition of microbiological data

Information on the minimum inhibitory concentration (MIC) values of amoxicillin, amoxicillin/clavulanate and ceftriaxone from 373 paediatric strains of S. pneumoniae and 438 of H. influenzae was extracted from the SAUCE 3 surveillance and provided by the Medical Department of GlaxoSmithKline. The clinical isolates of S. pneumoniae and H. influenzae were obtained from community-acquired respiratory tract infections and collected between November 2001 and October 2002. Around 49% of the S. pneumoniae and 32% of the H. influenzae isolates were from middle ear samples, whereas 32% and 67%, respectively, were collected from lower respiratory tract and 18% and 1.5% respectively, from blood. A complete description of study is provided in Reference 6.

Monte Carlo simulation

The following drug regimens were evaluated: amoxicillin and amoxicillin/clavulanate 20 mg/kg, 40 mg/kg, 45 mg/kg and 50 mg/kg every 12 h (q12 h) and 13 mg/kg, 27 mg/kg, 30 mg/kg and 33 mg/kg every 8 h (q8 h) orally; ceftriaxone 50 mg/kg and 100 mg/kg intramuscularly and intravenously, single dose and a 3-day regimen. A 5000 subject Monte Carlo simulation was employed to recreate steady-state free drug plasma concentration-time profiles on the basis of models and model parameter estimates reported previously in paediatrics.

Amoxicillin profiles were generated using the information provided by Canafax et al., assuming a one-compartment model. The mean population values for apparent volume of distribution (V/F), first order elimination rate constant (K), and first order absorption rate constant (Ka) were 1.44 L/kg, 0.276 h⁻¹, and 1.77 h⁻¹, respectively. The value of the unbound fraction (fu) in plasma was 0.8. The values for interindividual variability (IVV) (expressed as coefficient of variation) were 26%, 50% and 56%, respectively.

Ceftriaxone plasma concentration-time profiles were created based on a recent pharmacokinetic evaluation. A three-compartment model was used with the following pharmacokinetic parameter values (IVV expressed as coefficient of variation in parenthesis): V/F (L): 2.13 (84); apparent total plasma clearance [CL/F (L/h)]: 0.556 (27); K23 (h⁻¹): 3.12 (78); K32 (h⁻¹): 5.78 (37); K24 (h⁻¹): 4.73 (69); K42 (h⁻¹): 6.13 (61), where the K’s correspond to the first order rate distribution constant between the central and peripheral compartments, or absorption. When intramuscular administration was considered, bioavailability (F) and Ka (h⁻¹) of 1 and 3.09 (183), were used.

All simulations were performed with NONMEM (Version V, Level 1.1, Globomax LLC, Hanover, MD). Individual pharmacokinetic parameters were assumed to follow a log-normal distribution with absence of covariance. The values used for fu and F during the simulation exercise were the typical population estimates. Unbound plasma concentrations were simulated without residual error.

For amoxicillin and amoxicillin/clavulanate, pharmacodynamic exposures for simulated dose regimens were assessed as follows.
The time that free drug concentrations were maintained above the MIC ($f_{T>MIC}$) was determined using the Splus software (Insightful, Seattle, WA). The provability of target attainment (PTA) was calculated by counting the subjects who achieved $f_{T>MIC}$ for at least 50% of the dosing interval. The cumulative fraction of response (CFR) for each dose administration regimen was calculated by multiplying the PTA at each MIC by the fraction of organism susceptible at that concentration of the respective MIC distribution. The sum of those individual products is the CFR, and can be interpreted as the probability of successful treatment of infections caused by bacteria with a specific susceptibility pattern in the population studied.

In the case of ceftriaxone, in determining the amount that free plasma concentrations need to exceed MICs to achieve bacteriological eradication, the frequency of times above the MIC for 24, 48, 72, 96, and 120 hours was evaluated. CFR was calculated as the probability to achieve $f_{T>MIC}$ considering the MIC distribution.

Results

Figures 1 and 2 show the antimicrobial susceptibility of *S. pneumoniae* and *H. influenzae* paediatric strains to amoxicillin and amoxicillin/clavulanate, respectively. According to breakpoints
Table 1  
Expected cumulative fractions of response (CFR) for amoxicillin and amoxicillin/clavulanate. The target chosen was 50% of unbound concentration above the MIC. For amoxicillin/clavulanate, only amoxicillin doses are indicated.

<table>
<thead>
<tr>
<th>CFR (%)</th>
<th>S. pneumoniae</th>
<th>H. influenzae</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 mg/kg q12h</td>
<td>83</td>
<td>78</td>
</tr>
<tr>
<td>40 mg/kg q12h</td>
<td>91</td>
<td>82</td>
</tr>
<tr>
<td>45 mg/kg q12h</td>
<td>92</td>
<td>83</td>
</tr>
<tr>
<td>50 mg/kg q12h</td>
<td>93</td>
<td>83</td>
</tr>
<tr>
<td>13 mg/kg q8h</td>
<td>89</td>
<td>82</td>
</tr>
<tr>
<td>27 mg/kg q8h</td>
<td>95</td>
<td>85</td>
</tr>
<tr>
<td>30 mg/kg q8h</td>
<td>96</td>
<td>85</td>
</tr>
<tr>
<td>33 mg/kg q8h</td>
<td>96</td>
<td>86</td>
</tr>
</tbody>
</table>

| Amoxicillin/clavulanate |               |               |
| 20 mg/kg q12h | 89 | 85 |
| 40 mg/kg q12h | 94 | 93 |
| 45 mg/kg q12h | 95 | 94 |
| 50 mg/kg q12h | 95 | 95 |
| 13 mg/kg q8h | 93 | 93 |
| 27 mg/kg q8h | 97 | 98 |
| 30 mg/kg q8h | 97 | 98 |
| 33 mg/kg q8h | 97 | 99 |

q12h, every 12 h; q8h, every 8 h.

Recommended by CLSI for non-meningeal infections, both were very active against S. pneumoniae and H. influenzae, with susceptibilities >90%. Amoxicillin/clavulanate was also very active against H. influenzae, with a susceptibility of 100%, but amoxicillin was less active. Among H. influenzae isolates, 15.5% were β-lactamase positive-ampicillin resistant strains and 2.7% were β-lactamase negative ampicillin resistant strains, presenting diminished susceptibility to ampicillin with MIC ≥ 2 mg/L.

The results of the analysis of the PTA by MIC for both antibiotics are also shown in Figures 1 and 2. The achieved PTA with high doses (≥ 80 mg/kg/day) was >80% up to an MIC of 2 mg/L. The PTA with the lowest doses was also higher than 80% up to an MIC of 1 mg/L.

Table 1 shows the assessment of CFR for amoxicillin and amoxicillin/clavulanate. When amoxicillin was evaluated, CFR varied from 83% to 96% against S. pneumoniae, and from 78% to 86% against H. influenzae. For amoxicillin/clavulanate, CFR was always >85%.

Figure 3 shows the antimicrobial susceptibility for ceftriaxone. This antibiotic was very active against S. pneumoniae and H. influenzae, with susceptibilities of 96% and 100%, respectively. Figure 4 shows ceftriaxone target attainment to maintain free drug concentration above the MIC at 24, 48, 72, 96 and 120 hours for all posologies. When a single dose of 50 mg/kg im ceftriaxone was simulated, the proportion of virtual patients with free plasma concentrations that exceeded the MICs of 0.015, 0.03, 0.125 and 0.25 mg/L at 24 hours was 85%, 83%, 80%, 77% and 73%, respectively. These values decreased further as time after dosing increased (at 48, 72, 96 and 120 hours post-dose). Slightly more favourable results were achieved with the highest dose (100 mg/kg iv or im). Considering the antimicrobial susceptibility of H. influenzae to ceftriaxone (99.8% isolates presented MICs ≤ 0.25 mg/L), all dose regimens provided t > MIC longer than 24 hours in more than 70% of the patients. However, a significant number of strains had MICs of 1 mg/L (16.6%) or 2 mg/L (3.5%) against S. pneumoniae. In these cases, target attainment at 24 hours decreased significantly (50% for 50 mg/kg and 60% for 100 mg/kg). Consecutively, CFR values were higher for H. influenzae than for S. pneumoniae (Table 2). When the 3-day regimen is considered, the probability to achieve t > MIC for 72, 96 and 120 hours significantly increased compared to the single dose.

Discussion

Considering that AOM is typically treated empirically, the treatment of choice should target the most frequently isolated pathogens. In this study, PK/PD simulations were performed to evaluate different dose regimens of amoxicillin, amoxicillin/clavulanate and ceftriaxone, taking into account the antimicrobial susceptibility of paediatric strains of the two main pathogens responsible for the disorder in Spain, S. pneumoniae and H. influenzae, together with the pharmacokinetic variability in paediatric population.

When PK/PD principles are employed, PK and PD profiles of antimicrobials at infection site should be taken into account. However, we have used unbound plasma drug concentrations to

Figure 3. MIC distribution of ceftriaxone against 373 paediatric strains of S. pneumoniae (white bars) and 438 paediatric strains of H. influenzae (grey bars).
Moreover, when the parameter that predicts high-dose amoxicillin was needed, at 36 hours of free concentrations in tonsil tissue that exceeded 65%. This value, lower than those obtained in our study, could be explained by the regional susceptibility patterns. Amoxicillin susceptibility against *S. pneumoniae* and *H. influenzae* was documented in 80.6% and 54.5% of isolates from the GRASP study, whereas in SAUCE 3 it was 90.1% and 81.7%, respectively. These discrepancies justify different recommendations for empirical antibiotic treatment. Considering our results, high-dose amoxicillin should be confirmed as the first-line choice for children with AOM in Spain (CFR > 90%). In patients who have severe illness, and in those for whom additional coverage for *H. influenzae* is desired, selected therapy should be amoxicillin/clavulanate. Studies carried out in the US and Israel, recommend high-dose amoxicillin/clavulanate (90 mg/kg/day), but 13 mg/kg q8 h provides a high probability of achieving the requisite pharmacodynamic exposure in Spain (CFR > 90%).

The strains not covered by either amoxicillin or amoxicillin/clavulanate would be responsible for the failure of the treatment with these agents. Dagan observed that apart from amoxicillin/clavulanate, ceftriaxone was the only agent that successfully prevented bacterial persistence for the pathogens involved in AOM. For this drug, the target of continuously achieving 36 hours of free concentrations in tonsil tissue that exceeded was higher than 80%. However, when *H. influenzae* is the pathogen involved, high-dose amoxicillin had an 82–86% likelihood of achieving the target pharmacodynamic exposure, but CFR > 90% was never achieved. When considering amoxicillin/clavulanate, a CFR < 90% was only obtained when 20 mg/kg q12 h was simulated.

Current AOM management guidelines recommend high-dose amoxicillin as the first-line drug of choice in children. However, the probability of a successful outcome of high-dose amoxicillin against *H. influenzae* calculated using the Global Respiratory Antimicrobial Surveillance Project (GRASP) database was lower than 65%. This value, lower than those obtained in our study, could be explained by the regional susceptibility patterns. Amoxicillin susceptibility against *S. pneumoniae* and *H. influenzae* was documented in 80.6% and 54.5% of isolates from the GRASP study, whereas in SAUCE 3 it was 90.1% and 81.7%, respectively. These discrepancies justify different recommendations for empirical antibiotic treatment. Considering our results, high-dose amoxicillin should be confirmed as the first-line choice for children with AOM in Spain (CFR > 90%). In patients who have severe illness, and in those for whom additional coverage for *H. influenzae* is desired, selected therapy should be amoxicillin/clavulanate. Studies carried out in the US and Israel, recommend high-dose amoxicillin/clavulanate (90 mg/kg/day), but 13 mg/kg q8 h provides a high probability of achieving the requisite pharmacodynamic exposure in Spain (CFR > 90%).

The strains not covered by either amoxicillin or amoxicillin/clavulanate would be responsible for the failure of the treatment with these agents. Dagan observed that apart from amoxicillin/clavulanate, ceftriaxone was the only agent that successfully prevented bacterial persistence for the pathogens involved in AOM. For this drug, the target of continuously achieving 36 hours of free concentrations in tonsil tissue that exceeded

---

**Figure 4.** Ceftriaxone target attainment for maintaining free drug concentrations above MIC. The figure shows the ceftriaxone time above MIC in plasma with target attainment at 24 h (filled diamond), 48 h (open square), 72 h (filled triangle), 96 h (cross) and 120 h (open circle).

---

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>S. pneumoniae</th>
<th>H. influenzae</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 h</td>
<td>100 mg/Kg IV</td>
<td></td>
</tr>
<tr>
<td>48 h</td>
<td>64 32 16 8 4 2 1 0,5 0,25 0,125</td>
<td></td>
</tr>
<tr>
<td>72 h</td>
<td>64 32 16 8 4 2 1 0,5 0,25 0,125</td>
<td></td>
</tr>
<tr>
<td>96 h</td>
<td>64 32 16 8 4 2 1 0,5 0,25 0,125</td>
<td></td>
</tr>
<tr>
<td>120 h</td>
<td>64 32 16 8 4 2 1 0,5 0,25 0,125</td>
<td></td>
</tr>
</tbody>
</table>

---

**Table 2 Expected cumulative fractions of response (CFR) for ceftriaxone.** The target chosen was /T>MIC at 24, 48, 72, 96 and 120h.

---

sd: single dose.
the MIC has been considered as the criterion for defining microbiological success in the treatment of tonsillitis.

A target for treatment of AOM has not been established; this is why we calculated the probability to achieve plasma free drug concentrations above the MIC at 24, 48, 72, 96 and 120 h.

Leibovitz et al.20 showed a 48% bacteriological failure rate with a single 50 mg/kg ceftriaxone dose against penicillin-susceptible S. pneumoniae. Our results do not reflect such a high probability of treatment failure, as a susceptibility of 96% was documented in SAUCE 3, whereas 17–20% of strains isolated in the Leibovitz study were non-susceptible to ceftriaxone.

Estimated CFRs of ceftriaxone for H. influenzae are lower than expected, if we consider that 100% of the Spanish strains are susceptible (MICs ≤ 1 mg/L). This could be due to the fact that the target we chose may not be the most suitable one. The time above the MIC during the 24-h dosing interval for MEF is much greater than the $T_{\text{MIC}}$ in serum. Therefore, a more favourable scenario could be expected if we consider MEF concentrations instead of unbound plasma concentrations. Hence, the search for an adequate target for ceftriaxone in AOM is necessary, as Blumer established for tonsillitis and availability of clinical data on microbiological success rate is very important in order to contrast these results.

Recently studies19,20 have documented that a 3-day ceftriaxone regimen is significantly superior to a 1-day one in the treatment of non-responsive AOM caused by penicillin-resistant S. pneumoniae. We showed that CFR is still higher than 70% for S. pneumoniae 72 h after starting a 3-day treatment, while it decreased significantly after 24 h with a single dose. However, pharmacodynamic exposure target for both one-day and three-day dose regimens should be better established and confirmed with clinical data.

In spite of the results reported above, the following issues should be considered. Firstly, paediatric pharmacokinetic data of antibiotics are scarce and are obtained from a non-homogeneous population in relation to age. This leads to large interindividual variability, which was included in our pharmacokinetic model. Secondly, we used microbiological data from paediatric isolates, but not all of them were recovered from patients with otitis media. The reason for including strains from MEF and from the lower respiratory tract is that the microorganisms from MEF are more resistant, since in Spain, samples from MEF are only collected from the more severe cases or recurrence of AOM. The selection of these strains will provide biased information on the success of empirical treatments. The use of strains from the lower respiratory tract will provide more realistic information of susceptibility of strains causing AOM. Thirdly, this study did not consider the changing microbiology of AOM after widespread use of heptavalent pneumococcal vaccine (PCV7), which has been described in different countries. PVC7 has not been included into the vaccination schedule in Spain. If this occurred, the coverage could be similar as for any other vaccine included in the vaccination schedule (95%). In that case, this could result in a shift in frequency of causative bacterial pathogens responsible for AOM, and the results observed with this simulation exercise would have to be recalculated. Finally, this study has been developed using susceptibility data representative of bacteria causing non-complicated AOM in Spain. Consequently, caution should be taken before applying these findings to complicated/refractory infections or to other countries with different pathogen distribution data or different susceptibility patterns. Moreover, susceptibility data are based on a collection of isolates from the SAUCE 3 project, obtained during 2000–2001 and they may have changed since then. In the event of significant modifications in susceptibilities from new available data, new PK/PD evaluations should be performed in order to detect changes in the efficacy profiles of the antimicrobials.

In conclusion, considering the current susceptibility of bacterial pathogens most frequently isolated in AOM in Spain, high-dose amoxicillin should be the first-line choice for children with uncomplicated or non-refractory infection. Amoxicillin/clavulanate will provide the highest CFR (>90%) against both S. pneumoniae and H. influenzae. Differences with other studies may be explained by variations in antibiotic susceptibility patterns between countries. Results obtained with one-day ceftriaxone regimen indicate that it would be insufficient to achieve an acceptable bacteriological success rate if S. pneumoniae is responsible for the infection. Administration of 3 daily consecutive doses increases bacteriological eradication. Additional clinical evaluations will be necessary to establish the best target attainment for the treatment of AOM with ceftriaxone.

**Conflict of interest**

The authors have no conflicts of interest to declare.

**Acknowledgements**

The authors would like to thank the Medical Department of GlaxoSmithKline for providing specific MIC distributions obtained from the SAUCE 3 surveillance.

Martín Herrero is an employee of GSK, without any other financial interests in the company.

**References**